{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "decreases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "uniprot:P15692",
      "entity_text" : "VEGF-",
      "entity_type" : "protein"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "uniprot:P17707",
      "entity_text" : "AMD",
      "entity_type" : "protein"
    },
    "hypothesis_information" : false
  },
  "verbose_text" : "To reduce the adverse effects of the VEGF- or VEGFR targeting systemic therapy to non cancerous patients, an intravitreal injection of bevacizumab or ranibizumab is applied for the treatment of neovascular AMD.",
  "reading_complete" : "2020-08-02T12:32:37Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-02T12:30:45Z",
  "trigger" : "reduce",
  "evidence" : [ "reduce the adverse effects of the VEGF- or VEGFR-targeting systemic therapy to non-cancerous patients, an intravitreal injection of bevacizumab or ranibizumab is applied for the treatment of neovascular AMD" ],
  "pmc_id" : "3812243",
  "score" : 0
}